Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
ID: 351208Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351208

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-009.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" under Funding Opportunity Number RFA-CA-24-009. This initiative aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance the assessment of cancer biology at the molecular and cellular levels, particularly for applications in early detection, diagnosis, treatment, and addressing health disparities. Funding is capped at $300,000 per year for a maximum of three years, with an estimated total of 10 awards available, amounting to $4.3 million for fiscal year 2025. Interested applicants must submit their proposals electronically via Grants.gov by the deadline of October 2, 2024, and are encouraged to reach out to NIH Grants Information at grantsinfo@nih.gov for any inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-009-Full-Announcement.html
    RFA-CA-24-009.html
    The National Institutes of Health (NIH) is inviting grant applications for the Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Cancer Research, under Funding Opportunity Number RFA-CA-24-009. This initiative aims to support exploratory research projects that develop and validate innovative technologies for assessing and analyzing cancer biology at the molecular and cellular levels. Applications must demonstrate prior feasibility progress and focus on substantial advancements beyond traditional capabilities. Scholars targeting improved cancer detection, diagnosis, treatment, and addressing health disparities are particularly encouraged to apply. Funding is limited to $300,000 per year for a total period of up to three years, with an estimated 10 awards expected for a total of $4.3 million in fiscal year 2025. Grant applications must adhere to specific requirements, including detailed technical validation strategies, and must be submitted electronically via Grants.gov. The application deadline is set for October 2, 2024, with early submissions recommended to mitigate potential errors. The program is part of the broader Innovative Molecular Analysis Technologies (IMAT) initiative, aiming to improve cancer-related research methodologies and ultimately benefit patient care.
    Similar Opportunities
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.
    Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management" (RFA-CA-24-018). This initiative aims to support cooperative agreements that focus on the enhancement of emerging informatics technologies to improve data acquisition, management, analysis, and dissemination across the cancer research continuum. The program is particularly significant as it seeks to advance technologies that have shown initial viability but require further development to achieve a broader impact in cancer research, addressing critical health disparities and improving patient outcomes. NIH anticipates funding approximately four awards totaling $3.6 million for fiscal year 2025, with individual budgets capped at $600,000 per year over a five-year period. Applications are due by November 15, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on developing and validating innovative technologies to enhance the quality of biospecimens used in cancer research, specifically addressing pre-analytical variations that can compromise sample integrity. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and seeks projects that demonstrate preliminary data supporting their feasibility, with a funding ceiling of $300,000 per year for up to three years. Applications are due by October 1, 2024, and interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)" aimed at supporting exploratory research projects that develop innovative technologies to enhance the quality of biospecimens used in cancer research. The initiative focuses on addressing pre-analytical degradation of cancer-relevant biospecimens during collection, processing, and storage, with the goal of improving sample integrity and utility for downstream analyses. This funding is particularly significant for advancing research in cancer biology, early detection, and treatment, while also addressing health disparities. Grants of up to $150,000 are available, with applications opening on March 1, 2024, and a submission deadline of October 1, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)." This initiative invites revision applications from currently funded NCI R01 research projects, encouraging applicants to enhance their original research by integrating innovative technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The goal is to foster interdisciplinary collaboration and accelerate scientific discovery in cancer research. Interested applicants can apply for grants of up to $150,000 annually for a maximum of two years, with applications accepted starting March 1, 2024, and a submission deadline of October 1, 2024. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at enhancing cancer research through innovative technologies. This initiative encourages currently funded NCI P30 Cancer Center Support Grants (CCSG) recipients to expand their research by integrating new technical approaches developed through the NCI's Innovative Molecular Analysis Technologies (IMAT) program. The program is designed to foster interdisciplinary collaboration and promote independent validation of emerging technologies, thereby accelerating scientific discovery in cancer research. Interested applicants can apply for up to $150,000 per year, with a total funding pool of approximately $600,000 available for up to three awards. Applications are due by 5 PM local time on October 2, 2024, and further inquiries can be directed to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-015.html.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)." This initiative aims to support the development of innovative informatics tools that enhance the acquisition, analysis, dissemination, and management of cancer-related data, focusing on areas such as biology, treatment, early detection, and health disparities. The program encourages collaboration with end-users to ensure the practical utility of the proposed technologies, with approximately $2.25 million available for 5-6 awards, each with a maximum budget of $300,000 per year for up to three years. Interested applicants should note that the application process opens on May 11, 2024, with a submission deadline of November 15, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at incorporating novel technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program to accelerate cancer research. This initiative encourages currently funded NCI P50 specialized centers to expand upon their original research questions by integrating innovative tools and methods, thereby promoting interdisciplinary collaboration and enhancing the rigor of ongoing studies. With a funding ceiling of $150,000 per year and a total of approximately $600,000 anticipated to support three awards for fiscal year 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Interested parties should submit their applications by October 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at supporting the validation of molecular, cellular, and imaging markers for cancer detection, diagnosis, and treatment. This initiative encompasses a two-phase cooperative agreement mechanism: the UH2 phase focuses on analytical validation of assays over a two-year period, while the UH3 phase supports clinical validation for up to three years, utilizing well-annotated biospecimens from clinical trials. The program emphasizes the importance of multidisciplinary collaboration to enhance the development of assays that can significantly improve cancer research and patient care. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 for the UH2 phase and up to $250,000 per year for the UH3 phase. Applications will be accepted starting January 19, 2024, with a final submission deadline of October 15, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.